Lucid Diagnostics (LUCD) Cash & Equivalents Growth (3y) (2023 - 2026)
Lucid Diagnostics (LUCD) Cash & Equivalents Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | -13.31% |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | 34.27% |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | 8.10% |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | 8.16% |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | 40.74% |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | -2.57% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 2.72% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 38.28% |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | 32.23% |
| 10 | Lucid Diagnostics | 176.73 Mn | 143.33 Mn | 55,000.00 | 0.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.85% |
| Mar 31, 2026 | -10.98% |
| Dec 31, 2025 | 15.59% |
| Sep 30, 2025 | 20.68% |
| Jun 30, 2025 | -1.61% |
| Mar 31, 2025 | -19.24% |
| Dec 31, 2024 | -25.31% |
| Sep 30, 2024 | 778.97% |
| Jun 30, 2024 | 123.54% |
| Mar 31, 2024 | 557.85% |
| Dec 31, 2023 | 454.22% |
| Sep 30, 2023 | 404.86% |